FY2026 Earnings Forecast for ARQT Issued By HC Wainwright

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Equities researchers at HC Wainwright reduced their FY2026 EPS estimates for Arcutis Biotherapeutics in a research report issued on Thursday, November 5th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of $0.25 per share for the year, down from their prior forecast of $0.44. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ Q4 2026 earnings at $0.16 EPS, Q4 2027 earnings at $0.24 EPS, FY2027 earnings at $0.67 EPS, FY2028 earnings at $1.25 EPS, FY2029 earnings at $1.62 EPS and FY2030 earnings at $1.83 EPS.

ARQT has been the subject of a number of other reports. Jefferies Financial Group reissued a “buy” rating and issued a $39.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, October 8th. Weiss Ratings raised Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 29th. Needham & Company LLC set a $40.00 price objective on Arcutis Biotherapeutics in a research note on Thursday. Cantor Fitzgerald started coverage on Arcutis Biotherapeutics in a research note on Thursday, October 15th. They issued an “overweight” rating and a $48.00 price objective for the company. Finally, Wall Street Zen lowered shares of Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Eight research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $39.75.

Arcutis Biotherapeutics Stock Up 2.5%

ARQT opened at $26.20 on Monday. Arcutis Biotherapeutics has a one year low of $19.30 and a one year high of $34.80. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.67 and a current ratio of 2.92. The stock has a market capitalization of $3.29 billion, a P/E ratio of 162.14 and a beta of 1.66. The business’s 50-day simple moving average is $27.21 and its 200-day simple moving average is $25.37.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.12). The firm had revenue of $143.92 million for the quarter, compared to analysts’ expectations of $142.59 million. Arcutis Biotherapeutics had a return on equity of 14.96% and a net margin of 5.88%.

Insiders Place Their Bets

In other news, Director Terrie Curran sold 38,200 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $25.03, for a total value of $956,146.00. Following the sale, the director directly owned 23,526 shares in the company, valued at $588,855.78. This represents a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick Burnett sold 943 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $31.86, for a total transaction of $30,043.98. Following the transaction, the executive vice president directly owned 116,649 shares of the company’s stock, valued at approximately $3,716,437.14. This trade represents a 0.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 115,632 shares of company stock valued at $3,332,961. 9.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Arcutis Biotherapeutics

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Arcutis Biotherapeutics during the second quarter worth $276,502,000. Bank of America Corp DE purchased a new stake in shares of Arcutis Biotherapeutics in the second quarter valued at $78,330,000. Jupiter Topco LLC purchased a new stake in shares of Arcutis Biotherapeutics in the second quarter valued at $36,989,000. Bamco Inc. NY acquired a new stake in shares of Arcutis Biotherapeutics during the second quarter valued at $32,857,000. Finally, Simplify Asset Management Inc. acquired a new position in Arcutis Biotherapeutics in the 3rd quarter valued at about $22,885,000.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California.

Arcutis primarily serves the U.S.